Prognostic significance of β-catenin and topoisomerase IIα in de novo acute myeloid leukemia

Chih G. Chen, Jyh Pyng Gau, Jie Yu You, Kuan Der Lee, An Bin Yu, Chang Hsien Lu, Jen Tsun Lin, Chieh Lan, Wan Hsia Lo, Jacqueline Ming Liu, Ching Fen Yang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The Wnt/β-catenin signaling is important for controlling self-renewal of hematopoietic stem cells and its constitutive activation has recently been documented in a significant proportion of acute myeloid leukemia (AML) cases. Topoisomerase IIα (Topo IIα) is a marker of cell proliferation and a crucial target for anthracycline cytotoxicity, the mainstay of management employed in AML. We retrospectively investigated the prognostic roles of β-catenin and topo IIα in a cohort of 59 patients with newly diagnosed AML by immunohistochemistry. Aberrant β-catenin expression was demonstrated in 13 patients (22%), and it was more likely to occur in those with unfavorable karyotypes. Advanced age and poor performance status adversely influenced the achievement of complete remission, while neither aberrant β-catenin expression nor enhanced topo IIα activity did. On multivariate survival analysis, four factors independently predicted a shortened overall survival: aberrant β-catenin expression, high topo IIα activity, poor-risk cytogenetics, and presence of at least one comorbidity factor. Our results suggest that both β-catenin and topo IIα independently predicted an adverse prognosis and might serve as new markers for risk stratification in AML patients. Am. J. Hematol.

Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalAmerican Journal of Hematology
Volume84
Issue number2
DOIs
Publication statusPublished - Feb 2009
Externally publishedYes

Fingerprint

Catenins
Type II DNA Topoisomerase
Acute Myeloid Leukemia
Anthracyclines
Survival Analysis
Hematopoietic Stem Cells
Karyotype
Cytogenetics
Comorbidity
Multivariate Analysis
Immunohistochemistry
Cell Proliferation
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Prognostic significance of β-catenin and topoisomerase IIα in de novo acute myeloid leukemia. / Chen, Chih G.; Gau, Jyh Pyng; You, Jie Yu; Lee, Kuan Der; Yu, An Bin; Lu, Chang Hsien; Lin, Jen Tsun; Lan, Chieh; Lo, Wan Hsia; Liu, Jacqueline Ming; Yang, Ching Fen.

In: American Journal of Hematology, Vol. 84, No. 2, 02.2009, p. 87-92.

Research output: Contribution to journalArticle

Chen, CG, Gau, JP, You, JY, Lee, KD, Yu, AB, Lu, CH, Lin, JT, Lan, C, Lo, WH, Liu, JM & Yang, CF 2009, 'Prognostic significance of β-catenin and topoisomerase IIα in de novo acute myeloid leukemia', American Journal of Hematology, vol. 84, no. 2, pp. 87-92. https://doi.org/10.1002/ajh.21334
Chen, Chih G. ; Gau, Jyh Pyng ; You, Jie Yu ; Lee, Kuan Der ; Yu, An Bin ; Lu, Chang Hsien ; Lin, Jen Tsun ; Lan, Chieh ; Lo, Wan Hsia ; Liu, Jacqueline Ming ; Yang, Ching Fen. / Prognostic significance of β-catenin and topoisomerase IIα in de novo acute myeloid leukemia. In: American Journal of Hematology. 2009 ; Vol. 84, No. 2. pp. 87-92.
@article{09002103e63d44a09410ec2e2783fbc9,
title = "Prognostic significance of β-catenin and topoisomerase IIα in de novo acute myeloid leukemia",
abstract = "The Wnt/β-catenin signaling is important for controlling self-renewal of hematopoietic stem cells and its constitutive activation has recently been documented in a significant proportion of acute myeloid leukemia (AML) cases. Topoisomerase IIα (Topo IIα) is a marker of cell proliferation and a crucial target for anthracycline cytotoxicity, the mainstay of management employed in AML. We retrospectively investigated the prognostic roles of β-catenin and topo IIα in a cohort of 59 patients with newly diagnosed AML by immunohistochemistry. Aberrant β-catenin expression was demonstrated in 13 patients (22{\%}), and it was more likely to occur in those with unfavorable karyotypes. Advanced age and poor performance status adversely influenced the achievement of complete remission, while neither aberrant β-catenin expression nor enhanced topo IIα activity did. On multivariate survival analysis, four factors independently predicted a shortened overall survival: aberrant β-catenin expression, high topo IIα activity, poor-risk cytogenetics, and presence of at least one comorbidity factor. Our results suggest that both β-catenin and topo IIα independently predicted an adverse prognosis and might serve as new markers for risk stratification in AML patients. Am. J. Hematol.",
author = "Chen, {Chih G.} and Gau, {Jyh Pyng} and You, {Jie Yu} and Lee, {Kuan Der} and Yu, {An Bin} and Lu, {Chang Hsien} and Lin, {Jen Tsun} and Chieh Lan and Lo, {Wan Hsia} and Liu, {Jacqueline Ming} and Yang, {Ching Fen}",
year = "2009",
month = "2",
doi = "10.1002/ajh.21334",
language = "English",
volume = "84",
pages = "87--92",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Prognostic significance of β-catenin and topoisomerase IIα in de novo acute myeloid leukemia

AU - Chen, Chih G.

AU - Gau, Jyh Pyng

AU - You, Jie Yu

AU - Lee, Kuan Der

AU - Yu, An Bin

AU - Lu, Chang Hsien

AU - Lin, Jen Tsun

AU - Lan, Chieh

AU - Lo, Wan Hsia

AU - Liu, Jacqueline Ming

AU - Yang, Ching Fen

PY - 2009/2

Y1 - 2009/2

N2 - The Wnt/β-catenin signaling is important for controlling self-renewal of hematopoietic stem cells and its constitutive activation has recently been documented in a significant proportion of acute myeloid leukemia (AML) cases. Topoisomerase IIα (Topo IIα) is a marker of cell proliferation and a crucial target for anthracycline cytotoxicity, the mainstay of management employed in AML. We retrospectively investigated the prognostic roles of β-catenin and topo IIα in a cohort of 59 patients with newly diagnosed AML by immunohistochemistry. Aberrant β-catenin expression was demonstrated in 13 patients (22%), and it was more likely to occur in those with unfavorable karyotypes. Advanced age and poor performance status adversely influenced the achievement of complete remission, while neither aberrant β-catenin expression nor enhanced topo IIα activity did. On multivariate survival analysis, four factors independently predicted a shortened overall survival: aberrant β-catenin expression, high topo IIα activity, poor-risk cytogenetics, and presence of at least one comorbidity factor. Our results suggest that both β-catenin and topo IIα independently predicted an adverse prognosis and might serve as new markers for risk stratification in AML patients. Am. J. Hematol.

AB - The Wnt/β-catenin signaling is important for controlling self-renewal of hematopoietic stem cells and its constitutive activation has recently been documented in a significant proportion of acute myeloid leukemia (AML) cases. Topoisomerase IIα (Topo IIα) is a marker of cell proliferation and a crucial target for anthracycline cytotoxicity, the mainstay of management employed in AML. We retrospectively investigated the prognostic roles of β-catenin and topo IIα in a cohort of 59 patients with newly diagnosed AML by immunohistochemistry. Aberrant β-catenin expression was demonstrated in 13 patients (22%), and it was more likely to occur in those with unfavorable karyotypes. Advanced age and poor performance status adversely influenced the achievement of complete remission, while neither aberrant β-catenin expression nor enhanced topo IIα activity did. On multivariate survival analysis, four factors independently predicted a shortened overall survival: aberrant β-catenin expression, high topo IIα activity, poor-risk cytogenetics, and presence of at least one comorbidity factor. Our results suggest that both β-catenin and topo IIα independently predicted an adverse prognosis and might serve as new markers for risk stratification in AML patients. Am. J. Hematol.

UR - http://www.scopus.com/inward/record.url?scp=59949096098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59949096098&partnerID=8YFLogxK

U2 - 10.1002/ajh.21334

DO - 10.1002/ajh.21334

M3 - Article

VL - 84

SP - 87

EP - 92

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -